$130.28
0.85% today
Nasdaq, Sep 16, 08:12 pm CET
ISIN
US4523271090
Symbol
ILMN

Illumina Stock price

$129.18
+9.46 7.90% 1M
-0.19 0.14% 6M
-6.48 4.78% YTD
-17.72 12.06% 1Y
-312.01 70.72% 3Y
-164.00 55.94% 5Y
-34.60 21.13% 10Y
Nasdaq, Closing price Fri, Sep 13 2024
+2.93 2.32%
ISIN
US4523271090
Symbol
ILMN
Sector
Industry

Key metrics

Market capitalization $20.58b
Enterprise Value $22.51b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 63.22
EV/Sales (TTM) EV/Sales 5.08
P/S ratio (TTM) P/S ratio 4.65
P/B ratio (TTM) P/B ratio 14.30
Revenue growth (TTM) Revenue growth -0.72%
Revenue (TTM) Revenue $4.43b
EBIT (operating result TTM) EBIT $492.00m
Free Cash Flow (TTM) Free Cash Flow $356.00m
Cash position $994.00m
EPS (TTM) EPS $-19.17
P/E forward negative
P/S forward 4.71
EV/Sales forward 5.15
Short interest 3.18%
Show more

Create a Free Account to create an Illumina alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Illumina Stock Analysis

Analyst Opinions

27 Analysts have issued a Illumina forecast:

14x Buy
52%
12x Hold
44%
1x Sell
4%

Analyst Opinions

27 Analysts have issued a Illumina forecast:

Buy
52%
Hold
44%
Sell
4%

Financial data from Illumina

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '23
+/-
%
4,504 4,504
2% 2%
100%
- Direct Costs 1,754 1,754
9% 9%
39%
2,750 2,750
7% 7%
61%
- Selling and Administrative Expenses 1,082 1,082
20% 20%
24%
- Research and Development Expense 1,330 1,330
1% 1%
30%
338 338
55% 55%
8%
- Depreciation and Amortization 432 432
10% 10%
10%
EBIT (Operating Income) EBIT -94 -94
127% 127%
-2%
Net Profit -1,161 -1,161
74% 74%
-26%

In millions USD.

Don't miss a Thing! We will send you all news about Illumina directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Illumina Stock News

Neutral
PRNewsWire
7 days ago
MIAMI , Sept. 9, 2024 /PRNewswire/ -- The FDA has granted approval on Illumina's TruSight Oncology Comprehensive Assay, marking a transformative milestone in cancer diagnostics.
Neutral
PRNewsWire
13 days ago
SAN DIEGO , Sept. 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, welcomes the European Court of Justice's (ECJ's) judgment today ruling that the European Commission did not have jurisdiction over Illumina's acquisition of GRAIL.
Positive
Reuters
13 days ago
Europe's top court on Tuesday backed U.S. gene sequencing company Illumina's fight against EU antitrust regulators' investigation into its $7.1 billion bid for cancer diagnostic test maker Grail.
More Illumina News

Company Profile

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Head office United States
CEO Jacob Thaysen
Employees 12,010
Founded 1998
Website www.illumina.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today